Chicago Islet Consortium ICR at UIC

UIC 的芝加哥小岛联盟 ICR

• 批准号: 7501060
• 负责人: Jose Oberholzer
• 金额: $ 4.73万
• 依托单位: UNIVERSITY OF ILLINOIS AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-09-30 至 2009-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7501060
• 关键词: Accounting; Address; American; Antioxidants; Arts; Biopsy; Bioreactors; Blindness; Blood Glucose; Cardiovascular Diseases; Cell Therapy; Cell Transplantation; Cells; Centrifugation; Chicago; Chronic; Clinical; Clinical Protocols; Collaborations; Collection; Communities; Complex; Core Facility; Development; Diabetes Mellitus; Endocrine; Failure; Freedom; Funding; Glucose; Glutamine; Hemoglobin; Hormones; Human; Hypoglycemia; Hypoglycemic Agents; Illinois; Incubators; Infusion procedures; Institution; Insulin; Insulin-Dependent Diabetes Mellitus; International; Islet Cell; Islets of Langerhans; Islets of Langerhans Transplantation; Italy; Kidney Failure; Laboratories; Laboratory Study; Medicine; Methods; Numbers; Oxidative Stress; Oxygen; Pancreas; Patients; Phase; Practice Guidelines; Predictive Factor; Predictive Value; Preparation; Procedures; Process; Production; Purpose; Quality Control; Recovery of Function; Replacement Therapy; Research; Research Personnel; Resources; Shipping; Ships; Source; Techniques; Testing; Texas; Transplantation; Transportation; United States Food and Drug Administration; Universities; Warm Ischemia; base; blood glucose regulation; cell preparation; clinical application; college; diabetic; flasks; improved; in vivo; islet; neuronal cell body; prevent; programs; research and development; type I diabetic

Type I diabetes results from the body's failure to produce insulin, the hormone that "unlocks" the cells of the body, allowing glucose to enter and fuel them. It is estimated that 20.8 Million Americans have diabetes; type I diabetes accounts for 5 to 10%of cases (approximately 1.56 Million type I diabetic patients). Keeping blood glucose levels under tight control represents the most effective way either to prevent the onset or to reduce the progression of the chronic complications of type I diabetes, such as blindness, kidney failure and cardiovascular diseases. Islet transplantation can achieve insulin independence, glucose control and freedom of hypoglycemic attacks in patients afflicted with Type I diabetes mellitus. However, the recovery of functional pancreatic islets from cadaveric donor pancreata is a complex procedure and needs to be optimized. Until an unlimited source of human pancreatic islet cell becomes available, the further development of endocrine replacement therapy for the treatment of diabetes will solely depend on the availability of high quality islet preparations, both for clinical application and laboratory-based research. Because of the complexity of the islet isolation procedure, it would be desirable to concentrate the know-how in a limited number of centers or consortiums to allow for optimal use of available resources. The aim of this application is to extend the existing human islet core facility at the University of Illinois and the Chicago Islet Consortium into a federally funded Islet Cell Resource Center to isolate, purify, characterize and distribute human pancreatic islet cells for both transplantation into diabetic patients and use in laboratory studies to a larger community. The ICR at UIC with its partners in the Chicago Islet Consortium will be responsible for the procurement of whole pancreata, isolation and quality control of islet cell preparations, and distribution of islets for approved research or clinical protocols. The ICR at UIC is conducting research and development to improve isolation techniques, cellular viability and function, and shipping procedures, and is investigating methods for improved assessment of islet mass, composition, quality and viability. In addition, and most importantly for the progres of the field, the ICR at UIC will continue to provide large numbers of high-quality islet preparations for transplantation in diabetic patients.

I 型糖尿病是由于身体无法产生胰岛素而导致的，胰岛素是“解锁”细胞的激素。 身体，让葡萄糖进入并为它们提供燃料。据估计，有 2080 万美国人患有糖尿病； I型糖尿病占病例的5%至10%（约156万I型糖尿病患者）。保持 严格控制血糖水平是预防发病或预防糖尿病的最有效方法。 减少 I 型糖尿病慢性并发症的进展，例如失明、肾衰竭和 心血管疾病。胰岛移植可以实现胰岛素独立、血糖控制和 患有 I 型糖尿病的患者不会出现低血糖发作。然而，恢复 从尸体供体胰腺中提取功能性胰岛是一个复杂的过程，需要 优化。在人类胰岛细胞的无限来源变得可用之前，进一步 治疗糖尿病的内分泌替代疗法的发展完全取决于 提供高质量的胰岛制剂，用于临床应用和实验室研究。 由于胰岛分离过程的复杂性，需要集中专业知识 在有限数量的中心或联盟中，以实现现有资源的最佳利用。 该应用程序的目的是扩展伊利诺伊大学现有的人类胰岛核心设施， 芝加哥胰岛联盟成立联邦政府资助的胰岛细胞资源中心，以分离、纯化、 表征和分配人类胰岛细胞，用于移植到糖尿病患者中并使用 从实验室研究到更大的社区。 UIC 的 ICR 及其芝加哥小岛联盟的合作伙伴 将负责全胰的采购、胰岛细胞的分离和质量控制 为批准的研究或临床方案准备和分配胰岛。 UIC 的 ICR 是 进行研究和开发以改进分离技术、细胞活力和功能，以及 运输程序，并正在研究改进评估胰岛质量、成分、 质量和生存能力。 此外，对于该领域的进步最重要的是，UIC 的 ICR 将继续提供大量资金 大量用于糖尿病患者移植的高质量胰岛制剂。

项目成果

Conditional and specific inhibition of NF-κB in mouse pancreatic β cells prevents cytokine-induced deleterious effects and improves islet survival posttransplant.

条件性和特异性抑制小鼠胰腺β细胞中的NF-κB可防止细胞因子诱导的有害作用并提高移植后胰岛的存活率。

• 发表时间: 2012-02
• 影响因子: 3.8
• 作者: Rink, Jonathan S;Chen, Xiaojuan;Zhang, Xiaomin;Kaufman, Dixon B
• 通讯作者: Kaufman, Dixon B

Small interfering RNA-mediated suppression of proislet amyloid polypeptide expression inhibits islet amyloid formation and enhances survival of human islets in culture.

小干扰RNA介导的前胰岛淀粉样蛋白多肽表达抑制可抑制胰岛淀粉样蛋白形成并增强培养中人胰岛的存活率。

• 发表时间: 2008-11
• 影响因子: 7.7
• 作者: Marzban, Lucy;Tomas, Alejandra;Becker, Thomas C;Rosenberg, Lawrence;Oberholzer, Jose;Fraser, Paul E;Halban, Philippe A;Verchere, C Bruce
• 通讯作者: Verchere, C Bruce

Encapsulation of human islets in novel inhomogeneous alginate-ca2+/ba2+ microbeads: in vitro and in vivo function.

将人类胰岛封装在新型非均质藻酸盐-ca2/ba2 微珠中：体外和体内功能。

• 发表时间: 2008
• 作者: Qi, Meirigeng;Strand, Berit Lokensgard;Morch, Yrr;Lacik, Igor;Wang, Yong;Salehi, Payam;Barbaro, Barbara;Gangemi, Antonio;Kuechle, Joseph;Romagnoli, Travis;Hansen, Michael A;Rodriguez, Lisette A;Benedetti, Enrico;Hunkeler, David;Skjak
• 通讯作者: Skjak

Impairment of neurovascular coupling in Type 1 Diabetes Mellitus in rats is prevented by pancreatic islet transplantation and reversed by a semi-selective PKC inhibitor.

胰岛移植可预防大鼠 1 型糖尿病的神经血管耦合损伤，并可通过半选择性 PKC 抑制剂逆转。

• 发表时间: 2017-01-15
• 影响因子: 2.9
• 作者: Vetri, Francesco;Qi, Meirigeng;Xu, Haoliang;Oberholzer, Jose;Paisansathan, Chanannait
• 通讯作者: Paisansathan, Chanannait

Binding and leakage of barium in alginate microbeads.

藻酸盐微珠中钡的结合和渗漏。

• 发表时间: 2012-11
• 作者: Mørch, Yrr A;Qi, Meirigeng;Gundersen, Per Ole M;Formo, Kjetil;Lacik, Igor;Skjåk;Oberholzer, Jose;Strand, Berit L
• 通讯作者: Strand, Berit L